Abstract Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease characterized by autoantibodies against the hemidesmosomal proteins BP180 and BP230. The cell stress chaperone heat shock protein 90 (Hsp90) has been implicated in inflammatory responses, and recent evidence suggests that it represents a novel treatment target in autoimmune bullous diseases. The aim of the study was to investigate the contribution of Hsp90 to the proinflammatory cytokine production in keratinocytes induced by autoantibodies to BP180 from BP patient serum. HaCaT cells were treated with purified human BP or normal IgG in the absence or presence of the Hsp90 blocker 17-DMAG and effects on viability, interleukin 6 (IL-6) and IL-8 (cytokines critical for BP pathology), NFκB (their major transcription factor), and Hsp70 (marker of effective Hsp90 inhibition and potent negative regulator of inflammatory responses) were investigated. We found that BP IgG stimulated IL-6 and IL-8 release from HaCaT cells and that non-toxic doses of 17-DMAG inhibited this IL-8, but not IL-6 secretion in a dose-and time-dependent fashion.
Introduction
Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease characterized by an autoimmune response to two hemidesmosomal proteins within the dermal-epidermal junction, designated BP180 and BP230. The extracellular linker domain of BP180 termed noncollagenous 16A (NC16A) domain is considered to harbor major pathogenically relevant epitopes and is recognized by autoantibodies, which correlate with disease activity in the majority of BP patients (Schmidt and Zillikens 2013) . Insights into the functionally relevant pathogenic mechanisms in BP, which include complement activation, mast cell degranulation, recruitment and activation of neutrophils and eosinophils, and release of basal membrane zone-degradading proteinases from these effector cells, have been provided by in vitro studies using cultured human keratinocytes and ex vivo studies using cryosections of human skin as well as various mouse models, although the role of mast cells in models of antibody-mediated autoimmunity has recently been questioned (Kasperkiewicz and Zillikens 2007; Feyerabend et al. 2011; Schmidt and Zillikens 2013) . Although the precise sequence of these events is largely unknown, it has been proposed that one of the first steps leading to blister formation in BP comprise the binding of autoantibodies to BP180, thereby initiating Fc receptor-independent events leading to the release of interleukin 6 (IL-6) and IL-8 from basal keratinocytes (Schmidt et al. 2000 (Schmidt et al. , 2001 Messingham et al. 2011) . IL-8 is a potent chemoattractant for pathophysiologically relevant leukocyte effector cells and together with IL-6 known to be elevated in sera and blister fluids of BP patients and critical for blister formation in mouse models (Schmidt et al. 1996a, b; Liu et al. 1997; Inaoki and Takehara 1998; Chen et al. 2001; Nelson et al. 2006; Kobayashi 2008) .
Heat shock protein 90 (Hsp90) belongs to the group of ubiquitous molecular chaperones essential for protein folding and transport within the cell. It is strongly involved in participation of structural maturation and conformational regulation of a number of signaling molecules as well as transcription factors, which have been linked to synthesis of proinflammatory mediators and cytokines such as TNFα, IL-1, IL-6, and IL-8 (Salminen et al. 2008; Taipale et al. 2010; Henderson and Kaiser 2013) .
Pharmacological inhibition of Hsp90 function has therefore emerged as a promising method to ameliorate inflammatory cascades, as it has been demonstrated in various experimental mouse models of autoimmune diseases, including autoimmune encephalomyelitis (Dello Russo et al. 2006) , rheumatoid arthritis (Rice et al. 2008; Yun et al. 2011) , and systemic lupus erythematosus (Han et al. 2010; Shimp et al. 2012a) . Our own recent research work showed that, by downregulating T cell responses, this kind of treatment is also effective in mice with the experimentally induced subepidermal autoimmune blistering skin disease epidermolysis bullosa acquisita (Kasperkiewicz et al. 2011) . Moreover, we recently found first evidence suggesting that Hsp90 may play a pathophysiological role and represent a novel potential treatment target in patients with BP (Tukaj et al. 2013) .
In the present study, we show that pharmacological blockade of Hsp90 by the geldanamycin derivative 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) leads to suppression of IL-8 production from anti-BP180 IgG-stimulated HaCaT cells in a dose-and timedependent manner.
Materials and methods

Purification of IgG
Total serum IgG from a healthy blood donor and patient diagnosed with BP (based on typical clinical findings as well as on detection of linear deposits of IgG and C3 at the dermalepidermal junction and circulating IgG autoantibodies against BP180 NC16A by direct immunofluorescence microscopy and enzyme-linked immunosorbent assay [ELISA; Euroimmun, Lübeck, Germany], respectively) was isolated using Protein G Sepharose Fast Flow affinity column chromatography (GE Healthcare, Munich, Germany) as described previously (Tukaj et al. 2013) . Antibodies were eluted with 0.1 M glycin buffer (pH 2.8), neutralized with Tris-HCl (pH 9.0), and concentrated using Amicon Ultra-15 filters (Millipore, Bradford, MA, USA). Immunoreactivity of the affinity-purified BP IgG preparations was confirmed by indirect immunofluorescence microscopy on salt-split normal human skin (staining at the epidermal side of the artificial split) and by anti-BP180-NC16A-4X ELISA (Euroimmun, Lübeck, Germany) . No circulating anti-BP230 IgG autoantibodies were found in the patient's serum by ELISA (Euroimmun, Lübeck, Germany), and IL-6 and IL-8 concentrations in the IgG preparations were below the ELISA detection limit.
The collection of blood samples was approved by the Ethics Committee of the University of Lübeck, and informed consent was obtained according to the Declaration of Helsinki.
Cell culture
HaCaT cells were cultured in keratinocyte growth medium (Promo Cell, Heidelberg, Germany) supplemented with 10 % FCS at 37°C in 5 % CO 2 atmosphere. Cells were seeded on 24-or 12-well plates (Greiner Bio-One, Solingen, Germany) and grown to 80 % confluence. Cells were incubated with medium alone or with purified total IgG from a healthy blood donor and BP patient and cultured in absence or presence of 17-DMAG (InvivoGen, San Diego, CA, USA). After 24 h, cells were washed twice with PBS, trypsinized, harvested, washed with PBS again, lysed, and stored for further analysis at −20°C. For cytokine evaluation, culture supernatants were collected after 6, 12, and 24 h of incubation, and stored for further analysis at −20°C.
Lactate dehydrogenase cytotoxicity assay
Cytotoxicity of 17-DMAG was measured by a lactate dehydrogenase (LDH)-releasing assay using a Cytotoxicity Detection Kit (Roche, Mannheim, Germany) according to the manufacturer's protocol and quantified using an ELISA plate reader. Briefly, HaCaT cells were incubated with 17-DMAG at different concentrations (0.01, 0.1, 1, and 2.5 μM) for up to 24 h. Cell lysis was determined by measuring the amount of LDH released into culture medium.
Cytokine measurement BP IgG-treated HaCaT cells were cultured without or with different concentrations (0.01, 0.1, 1, and 2.5 μM) of 17-DMAG for 6, 12, and 24 h. IL-6 (BD, Heidelberg, Germany) and IL-8 (BD, Heidelberg, Germany) levels were analyzed in cell culture supernatants by ELISA according to the manufacturer's instructions.
Quantitative real-time polymerase chain reaction BP IgG-treated HaCaT cells were cultured without or with 1 μM of 17-DMAG for 12 h. Total RNA was isolated from cultured HaCaT cells using TRIzol reagent (Life Technologies) according to the manufacturer's instruction. Complementary DNA (cDNA) was reverse-transcribed from isolated RNA by incubating 1 μg of RNA with the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) following the manufacturer's instructions. Quantitative real-time polymerase chain reaction (RT-PCR) was performed in a Mastercycler (Eppendorf) using SYBR® Select Master Mix (Life Technologies). PCR mixtures contained 0.5 μM of each forward and reverse primers. Each reaction mixture was subjected to 2 min at 50°C and 2 min at 95°C followed by 40 cycles with 15 s at 95°C and 1 min at 60°C. Data was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The primers used in RT-PCR were as follows: IL-8 messenger RNA (mRNA), forward, 5′-ACC GGA AGG AAC CAT CTC AC -3′, and reverse, 5′-AAA CTG CAC CTT CAC ACA GAG -3′ and GAPDH, forward, 5′-ACA ACT TTG GTA TCG TGG AAG G -3′, and reverse, 5′-GCC ATC ACG CCA CAG TTT -3′.
Quantification of NFκB activation
BP IgG-treated HaCaT cells were cultured without or with 1 μM of 17-DMAG for 24 h. NFκB activity was analyzed in cell culture lysates by an NFκB p65 ELISA (Enzo, Lorrach, Germany) following the manufacturer's instruction.
Quantification of Hsp70 expression
BP IgG-treated HaCaT cells were cultured without or with 1 μM of 17-DMAG for 24 h. Hsp70 protein expression was analyzed in cell culture lysates by ELISA (Enzo, Lorrach, Germany) following the manufacturer's instruction.
Statistical analysis
Data was analyzed using Student's t test or one-way analysis of variance (ANOVA). A P value <0.05 was considered to indicate a statistically significant difference.
Results
17-DMAG dampens IL-8, but not IL-6 release from HaCaT cells, mediated by BP IgG
Using ELISA, we measured the effect of 17-DMAG, which was used in non-toxic doses throughout our experiments (Fig. 1) , on secretion of proinflammatory IL-6 and IL-8 cytokines by HaCaT cells stimulated with BP IgG. In the absence of 17-DMAG, BP IgG led to a significant release of both cytokines compared to normal IgG-treated cells (Figs. 2 and  3 ). The addition of 17-DMAG significantly inhibited the secretion of IL-8 in a dose-and time-dependent manner in both BP IgG-stimulated cells and cells cultured without IgG (Fig. 2) . In contrast, we found no significant inhibitory influence of 17-DMAG on IL-6 secretion (Fig. 3) .
17-DMAG blocks IL-8 mRNA expression in HaCaT cells, mediated by BP IgG
To investigate whether IL-8 inhibition by 17-DMAG takes place at the transcriptional level, IL-8 expression was assayed in BP IgG-stimulated HaCaT cells by RT-PCR. In fact, the addition of 17-DMAG significantly inhibited mRNA expression of this cytokine (Fig. 4) .
17-DMAG suppresses NFκB activity in HaCaT cells that were stimulated with BP IgG
To test whether Hsp90 inhibition had an impact on the activation status of NFκB, a major transcription factor regulating IL-8 synthesis (Hoffmann et al. 2002) , NFκB p65 subunit activity was measured in BP IgG-stimulated HaCaT cell lysates by ELISA. In the absence of 17-DMAG, BP IgG significantly stimulated NFκB p65 activity compared to normal IgG-treated cells. The presence of 17-DMAG led to a significant suppression of the activity of NFκB p65 (Fig. 5) .
17-DMAG upregulates Hsp70 expression in HaCaT cells that were stimulated with BP IgG
To confirm that the above-mentioned results were induced by Hsp90 inhibition, we investigated the expression of Hsp70, a common marker of effective Hsp90 inhibition (Dakappagari et al. 2010) , by ELISA using cell lysates of BP IgG-stimulated HaCaT cells. As expected, the addition of 17-DMAG resulted in significant induction of Hsp70 protein expression (Fig. 6 ).
Discussion
The rationale of our study to probe the effects of 17-DMAG on BP IgG-induced IL-6 and IL-8 production by HaCaT cells was mainly based on three documented findings: (i) both inflammatory cytokines play a key role in the pathophysiology of BP (Schmidt et al. 1996a, b; Liu et al. 1997; Inaoki and Takehara 1998; Schmidt et al. 2000; Chen et al. 2001; Schmidt et al. 2001; Nelson et al. 2006; Messingham et al. 2011) , (ii) the extensive list of Hsp90 client proteins includes many proinflammatory molecules (Salminen et al. 2008; Taipale et al. 2010; Henderson and Kaiser 2013) , and (iii) recent evidence suggests that Hsp90 represents a novel treatment target in autoimmune bullous diseases (Kasperkiewicz et al. 2011; Tukaj et al. 2013) .
The biological importance of proinflammatory cytokines in BP, especially of the strong leukocyte chemoattractant IL-8 (Kobayashi 2008) , has been implicated by the fact that (i) the concentration of this cytokine in serum and blister fluid of BP patients is correlated with disease activity and that (ii) blistering in complement component C5-or C4-deficient mice as well as mast cell-deficient mice, which are otherwise resistant to the pathogenic effect of antimurine BP180 IgG in the passive-transfer BP mouse model, is restored by intradermal injections of neutrophil-recruiting IL-8 (Schmidt et al. 1996a, b; Liu et al. 1997; Chen et al. 2001; Nelson et al. 2006; Kasperkiewicz and Zillikens 2007) . Similar to previous experiments, which showed that IgG or IgE autoantibodies from BP patients stimulated Fc receptorindependent production of IL-6 and IL-8 in primary cultures of normal human epithelial keratinocytes (NHEK) (Schmidt et al. 2000 (Schmidt et al. , 2001 Messingham et al. 2011) , we also observed a significant BP IgG-induced secretion of both cytokines compared to normal IgG using the HaCaT cell line. Cytokine background levels that were seen in medium containing normal IgG and which have also been reported by previous investigators may reflect the culture conditions on a plastic surface (and not human dermis) or may result from unspecific stimuli produced by keratinocytes (Schmidt et al. 2000 (Schmidt et al. , 2001 . Like in the previous studies, the purified BP IgG reacted with the NC16A domain of BP180 that is known to contain the major antigenic sites for most BP sera (Schmidt and Zillikens   Fig. 2 Evaluation of the effects of pharmacological Hsp90 inhibition on IL-8 secretion into culture medium by HaCaT cells treated with medium alone, 2 mg/ml IgG from a healthy volunteer (normal IgG), and 2 mg/ml IgG from a bullous pemphigoid patient (BP IgG) for 6, 12, and 24 h. These BP IgGstimulated and IgG-non-treated HaCaT cells were cultured in absence or presence of different non-toxic concentrations of 17-DMAG. IL-8 levels in cell culture supernatants were analyzed by ELISA. Results are mean±SEM of two separate experiments, each performed in triplicate. *P<0.05, **P<0.01, ***P<0.001 2013). Together with these previous observations and the recent finding that BP180-deficient epidermal keratinocytes display an abnormally high IL-8 response under various inflammatory stimuli (Van den Bergh et al. 2012), our current results support the assumption that targeting BP180 directly affects the epidermal keratinocyte proinflammatory cytokine response (Schmidt et al. 2000 (Schmidt et al. , 2001 Messingham et al. 2011; Van den Bergh et al. 2012) .
Through Hsp90 blockade, we observed a dose-and timedependent suppression of this BP IgG-mediated IL-8 release from HaCaT cells, which was at least in part mediated by inhibition of mRNA expression of this cytokine. In contrast, the IL-6 secretion was not disturbed in the presence of 17-DMAG under these conditions. Inhibition of IL-8 secretion by 17-DMAG was also found in cells not treated with the autoantibody, which may reflect suppression of constitutively expressed IL-8 in HaCaT cells rather than cytotoxic effects of this Hsp90 inhibitor as no such cytokine release was observed for IL-6 and cytotoxicity of 17-DMAG in the concentrations used was ruled out using the LDH assay. Similar results were previously obtained by Schmidt and colleagues using another immunomodulatory agent, the sulfone derivative dapsone (Schmidt et al. 2001 ). This drug is applied successfully in the treatment of different autoimmune bullous diseases associated with neutrophil or eosinophil skin Fig. 4 RT-PCR-based investigation of the impact of pharmacological Hsp90 inhibition on IL-8 mRNA expression in HaCaT cells treated with medium alone (dotted line) and 2 mg/ml IgG from a bullous pemphigoid patient (BP IgG) for 12 h. These BP IgG-stimulated HaCaT cells were cultured in absence or presence of 1 μM 17-DMAG. Data was normalized to the housekeeping gene GAPDH. Results are mean±SEM of two separate experiments, each performed in duplicate. *P<0.05 Fig. 3 Evaluation of the effects of pharmacological Hsp90 inhibition on IL-6 secretion into culture medium by HaCaT cells treated with medium alone, 2 mg/ml IgG from a healthy volunteer (normal IgG), and 2 mg/ml IgG from a bullous pemphigoid patient (BP IgG) for 6, 12, and 24 h. These BP IgGstimulated and IgG-non-treated HaCaT cells were cultured in absence or presence of different non-toxic concentrations of 17-DMAG. IL-6 levels in cell culture supernatants were analyzed by ELISA. Results are mean±SEM of two separate experiments, each performed in triplicate. *P<0.05, **P<0.01, ***P<0.001 infiltration, including BP, although hemolysis and concomitant anemia secondary to hemolysis are expected in most patients receiving this therapy (Gürcan and Ahmed 2009) . In their experiments, dapsone analogously inhibited the anti-BP IgG-induced IL-8 release from NHEK without affecting IL-6 secretion (Schmidt et al. 2001) .
The capacity of Hsp90 inhibitors to blunt IL-8 production was recently reported in the context of bacterial-and viralinduced inflammation, including Helicobacter pylori-infected gastric epithelial cells (Yeo et al. 2004) , Legionella pneumophila-infected lung epithelial cells (Teruya et al. 2007) , Bacteroides fragilis enterotoxin-treated intestinal epithelial cells (Kim et al. 2009) , and oncogenic herpes virusinfected endothelial cells and fibroblasts (Defee et al. 2011) . In these experimental studies, Hsp90 inhibitors acted via deactivation of NFκB, a client of Hsp90 and one of the major transcription factors for IL-8 (Hoffmann et al. 2002; Salminen et al. 2008) . Similarly, we could demonstrate that the activity of this transcription factor was upregulated in BP IgG-stimulated HaCaT cells and that this effect was abrogated in the presence of 17-DMAG. In this regard, it is worth noting that blockade of NFκB by its specific inhibitor Bay-11-7082 has recently been shown to result in normalization of the above-mentioned abnormally high IL-8 response in activated BP180-deficient epidermal keratinocytes ( Van den Bergh et al. 2012) . Taken together, this suggests that NFκB plays an important role in mediating anti-BP180 effects on the keratinocyte IL-8 response and that this inflammatory cell signaling event can be efficiently interrupted by Hsp90 blockade.
It remains unclear, why anti-BP IgG-induced IL-6 expression was not hampered in response to Hsp90 inhibition in our study, although NFκB is also known to be an important transcription factor for this cytokine and impairment of the inflammatory IL-6 pathway by Hsp90 blockade was previously demonstrated in various cell types (except keratinocytes) (Sato et al. 2003; Wax et al. 2003; Mitsiades et al. 2006; Lang et al. 2007; Ambade et al. 2012; Petersen et al. 2012; Shimp et al. 2012a, b) . Similar to our study, however, inhibition of NFκB by Bay-11-7082 suppressed the upregulation of different proinflammatory cytokines, but also did not compromise the IL-6 response in diaphragm muscle cells exposed to oxidative stress (Sigala et al. 2011) . One explanation for this and our finding could be that cytokine regulation may be cell type and tissue specific. It can be speculated that in case of keratinocyte-derived IL-6, for which the molecular events that regulate its induction are not yet fully clarified, production of this cytokine may be compensated by other transcription factors than NFκB, which may be less or not prone to Hsp90 inhibition.
Finally, we found upregulated Hsp70 protein levels in BPIgG-stimulated HaCaT cells after treatment with 17-DMAG. Hsp70 is generally accepted as a good marker for effective Hsp90 inhibition as its increased expression is known to result from Hsp90 blockade-induced activation and nuclear translocation of the transcription factor heat shock factor-1, which then drives the synthesis of this chaperone (Dakappagari et al. 2010; Collins et al. 2013) . Hsp70, in turn, is also regarded as a potent negative regulator of inflammatory responses through, but not limited to, its negative feedback effect on NFκB signaling activity (de Jong et al. 2009; Stocki and Dickinson 2012) . This suggests that, in addition to Hsp90 inhibition per se, Hsp70 itself may account for the anti-inflammatory effects seen in our study and warrants further investigation. In summary, this study provides important insights that Hsp90 is involved as crucial regulator in anti-BP180 IgGinduced production of keratinocyte-derived IL-8, one of the significant chemokines related to BP pathogenesis. By adding to the knowledge of the anti-inflammatory effects of Hsp90 blockade, our data further support the introduction of Hsp90 inhibitors into the clinical setting for treatment of autoimmune diseases, especially for BP.
